Top

Published in:

01-10-2009 | Original Article

Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis

Authors: Toshiaki Kogure, Hiroko Sato, Daijiro Kishi, Tomoyuki Ito, Takeshi Tatsumi

Published in: Rheumatology International | Issue 12/2009

Abstract

This study investigated the usefulness of biomarkers indicating beneficial response to traditional herbal medicine (THM) among patients with rheumatoid arthritis (RA). We assessed 34 RA patients who received keishinieppiittokaryojutsubu (KER), one of the representative THM. The observational term was 12 months, and we calculated the disease activity score of 28 joints every 3 months and evaluated the response to KER using European League Against Rheumatism (EULAR) response criteria. Additionally, serum levels of anti-cyclic citrullinated peptide antibody (ACPA) were measured by enzyme-linked immunosorbent assay at the baseline and after 6 and 12 months of the treatment with KER. As a result, 14 (41.2%) of the 34 patients were defined as responders, 13 as non-responders and 7 as out of assessment after 6 months, respectively. Pretreatment levels of serum ACPA were lower in KER responders than in non-responders (P = 0.042), although other univariate analysis did not show any significant differences in baseline clinical measures between the two groups. Furthermore, responders to KER showed a significant decrease in the serum levels of ACPA. These findings suggest that pretreatment serum levels of ACPA are a useful predictor of a good response to treatment with KER. Furthermore, a decrease in serum levels of ACPA may be an adjunctive indicator in predicting the efficacy of this kind of treatment.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328–346. doi:10.1002/art.10148 CrossRef

Kogure T, Hoshino A, Ito K, Sato H, Tatsumi T, Ohyama Y, Kawata E, Fujita K, Tamura J (2005) Beneficial effect of complementary alternative medicine on lymphedema with rheumatoid arthritis. Mod Rheumatol 15:445–449. doi:10.1007/s10165-005-0438-2 PubMedCrossRef

Niizawa A, Kogure T, Hai LX, Fujinaga H, Takahashi K, Shimada Y, Terasawa K (2003) Clinical and immunomodulatory effects of fun-boi, an herbal medicine, on collagen-induced arthritis in vivo. Clin Exp Rheumatol 21:57–62PubMed

Niizawa A, Kogure T, Fujinaga H, Takahashi K, Shimada Y, Terasawa K (2000) Clinical and immunomodulatory effects of fun-boi, an herbal medicine, in rheumatoid arthritis. J Clin Rheumatol 6:244–249. doi:10.1097/00124743-200010000-00002 PubMedCrossRef

Wessels JAM, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, Huizinga TWJ, Guchelaar H-J (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent onset rheumatoid arthritis. Arthritis Rheum 56:1765–1775. doi:10.1002/art.22640 PubMedCrossRef

Kogure T, Tatsumi T, Fujinaga H, Niizawa A, Terasawa K (2007) Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies. Mediators Inflamm 2007:12367 [Epub 2007 Mar 7]

Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MAFJ, Huizinga TWJ, Kruijsen MWM, Laan RFJM (2003) Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 62:423–426. doi:10.1136/ard.62.5.423 PubMedCrossRef

Kaltenhäuser S, Pierer M, Arnold S, Kamprad M, Baerwald C, Häntzschel H, Wagner U (2007) Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology (Oxford) 46:100–104. doi:10.1093/rheumatology/kel052 CrossRef

Sghiri R, Bouagina E, Zaglaoui H, Mestiri H, Harzallah L, Harrabi I, Ghannouchi M, Mokhtar F, Ghedira I (2007) Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int 27:1125–1130. doi:10.1007/s00296-007-0351-4 PubMedCrossRef

10.

Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324. doi:10.1002/art.1780310302 PubMedCrossRef

11.

Terasawa K (1993) Introduction. In: Terasawa K (ed) KAMPO Japanese-oriental medicine; insights from clinical cases. K.K. Standard McIntyre, Tokyo, pp 1–13

12.

Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, Iikuni N, Nawata M, Amano K, Shinozaki M, Takeuchi T (2007) Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan. Mod Rheumatol 17:28–32. doi:10.1007/s10165-006-0532-0 PubMedCrossRef

13.

Pincus T, Larsen A, Brooks RH, Kaye J, Nance EP, Callahan LF (1997) Comparison of 3 quantitative measures of hand radiographs in patients with rheumatoid arthritis: Steinbrocker stage, Kaye modified Sharp score, and Larsen score. J Rheumatol 24:2106–2112PubMed

14.

Komatireddy GR, Leitch RW, Cella K, Browning G, Minor M (1997) Efficacy of low load resistive muscle training in patients with rheumatoid arthritis functional class II and III. J Rheumatol 24:1531–1539PubMed

15.

Papadopoulos NG, Tsiaousis GZ, Pavlitou-Tsiontsi A, Giannakou A, Galanopoulou VK (2008) Does the presence of anti-CCP autoantibodies and their serum levels influence the severity and activity in rheumatoid arthritis patients? Clin Rev Allergy Immunol 34:11–15. doi:10.1007/s12016-007-8018-1 PubMedCrossRef

16.

Ogawa K, Kojima T, Matsumoto C, Kamegai S, Oyama T, Shibagaki Y, Muramoto H, Kawasaki T, Fujinaga H, Takahashi K, Hikiami H, Goto H, Kiga C, Koizumi K, Sakurai H, Shimada Y, Yamamoto M, Terasawa K, Takeda S, Saiki I (2007) Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clin Biochem 40:1113–1121. doi:10.1016/j.clinbiochem.2007.06.005 PubMedCrossRef

17.

Visser K, Verpoort KN, van Dongen H, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW, n Mil AH (2008) Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann Rheum Dis 67:1194–1195. doi:10.1136/ard.2008.088070 PubMedCrossRef

18.

Spadaro A, Riccieri V (2005) Methotrexate effect on anti-cyclic citrullinated peptide antibody levels in rheumatoid arthritis. Ann Rheum Dis 64:1241–1242. doi:10.1136/ard.2004.032136 PubMedCrossRef

19.

De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F (2005) Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 64:299–302. doi:10.1136/ard.2004.023523 PubMedCrossRef

20.

Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM (2005) Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 26:58–62. doi:10.1007/s00296-004-0571-9 PubMedCrossRef

21.

Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218–1221. doi:10.1136/ard.2003.014647 PubMedCrossRef

22.

Ahmed MM, Mubashir E, Wolf RE, Hayat S, Hall V, Shi R, Berney SM (2006) Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis. South Med J 99:1209–1215PubMed

23.

Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, Cantagrel A, Sibilia J, Combe B (2006) Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 8:R40 [Epub]. doi:10.1186/ar1896

Title: Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis
Authors: Toshiaki Kogure
Hiroko Sato
Daijiro Kishi
Tomoyuki Ito
Takeshi Tatsumi
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 12/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-009-0877-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2009

Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India

Serum homocysteine level in patients with ankylosing spondylitis

Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis

Two distinct patterns of ankylosing spondylitis in Moroccan patients

Early onset neutropenia after mycophenolate mofetil in systemic sclerosis

Identification of candidate genes for susceptibility to reactive arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page